Due to the observed effect of Tempol on HIF2α, CA9 and VEGF, all previously reported therapeutic targets for CCRCC tumors, we investigated whether Tempol might have an anti-tumor effect in CCRCC cells. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.